Alanoglu G, Kilbas S, Arslan C, Senol A, Kutluhan S
Department of Internal Medicine, Division of Hematology, School of Medicine, Suleyman Demirel University, 32100 Isparta, Turkey.
Mult Scler. 2007 Jun;13(5):683-5. doi: 10.1177/1352458506071333. Epub 2007 Mar 15.
A 31-year-old patient with multiple sclerosis (MS), treated with interferon beta-1b (IFNB-1b) for two years, presented with fatigue and dizziness. Coombs' positive autoimmune hemolytic anemia (AIHA) was found. Other potential etiologies of AIHA were ruled out. An association with IFNB-1b was highly suspected. Interferon therapy was discontinued and prednisone therapy instituted. There was resolution of the hemolytic anemia, and prednisone therapy was tapered gradually. To the best of our knowledge, there is no reported case of the development of AIHA associated with IFNB-1b use in MS patients. We conclude that if an unexplained drop in hematocrit occurs with a MS patient receiving IFNB-1b, autoimmune mediated hemolysis should also be considered.
一名31岁的多发性硬化症（MS）患者，接受β-1b干扰素（IFNB-1b）治疗两年，出现疲劳和头晕症状。发现其抗人球蛋白试验阳性的自身免疫性溶血性贫血（AIHA）。排除了AIHA的其他潜在病因。高度怀疑与IFNB-1b有关。停用干扰素治疗并开始使用泼尼松治疗。溶血性贫血得到缓解，泼尼松治疗逐渐减量。据我们所知，尚无MS患者使用IFNB-1b后发生AIHA的报道病例。我们得出结论，如果接受IFNB-1b治疗的MS患者出现无法解释的血细胞比容下降，也应考虑自身免疫介导的溶血。
